Many globular and natively disordered proteins can convert into amyloid fibrils. These fibrils are associated with numerous pathologies 1 as well as with normal cellular functions 2,3 , and frequently form during protein denaturation 4, 5 . Inhibitors of pathological amyloid fibril formation could be useful in the development of therapeutics, provided that the inhibitors were specific enough to avoid interfering with normal processes. Here we show that computer-aided, structure-based design can yield highly specific peptide inhibitors of amyloid formation. Using known atomic structures of segments of amyloid fibrils as templates, we have designed and characterized an all-D-amino-acid inhibitor of the fibril formation of the tau protein associated with Alzheimer's disease, and a non-natural L-amino-acid inhibitor of an amyloid fibril that enhances sexual transmission of human immunodeficiency virus. Our results indicate that peptides from structure-based designs can disrupt the fibril formation of full-length proteins, including those, such as tau protein, that lack fully ordered native structures. Because the inhibiting peptides have been designed on structures of dual-b-sheet 'steric zippers', the successful inhibition of amyloid fibril formation strengthens the hypothesis that amyloid spines contain steric zippers.
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Many globular and natively disordered proteins can convert into amyloid fibrils. These fibrils are associated with numerous pathologies 1 as well as with normal cellular functions 2, 3 , and frequently form during protein denaturation 4, 5 . Inhibitors of pathological amyloid fibril formation could be useful in the development of therapeutics, provided that the inhibitors were specific enough to avoid interfering with normal processes. Here we show that computer-aided, structure-based design can yield highly specific peptide inhibitors of amyloid formation. Using known atomic structures of segments of amyloid fibrils as templates, we have designed and characterized an all-D-amino-acid inhibitor of the fibril formation of the tau protein associated with Alzheimer's disease, and a non-natural L-amino-acid inhibitor of an amyloid fibril that enhances sexual transmission of human immunodeficiency virus. Our results indicate that peptides from structure-based designs can disrupt the fibril formation of full-length proteins, including those, such as tau protein, that lack fully ordered native structures. Because the inhibiting peptides have been designed on structures of dual-b-sheet 'steric zippers', the successful inhibition of amyloid fibril formation strengthens the hypothesis that amyloid spines contain steric zippers.
The finding that dozens of pathologies, including Alzheimer's disease, are associated with amyloid fibrils has stimulated research on fibril inhibition. One approach uses the self-associating property of proteins that form fibrils to poison fibril formation with short peptide segments [6] [7] [8] [9] [10] [11] . A second approach is based on screening for molecules that can disrupt fibril formation 12, 13 . Here we take a third approach to fibril inhibition: structure-based design of non-natural peptides targeted to block the ends of fibrils. With advanced sampling techniques and by minimizing an appropriate energy function, we identify novel candidate inhibitors computationally from a large peptide space that interact favourably with our template structure. This approach has been made possible by the determination of several dozen fibril-like atomic structures of segments from amyloid-forming proteins [14] [15] [16] . These structures reveal a common motif called a steric zipper, in which a pair of b-sheets is held together by the interdigitation of their side chains 14 . Using as templates the steric-zipper structures formed by segments of two pathological proteins, we have designed inhibitors that cap fibril ends. As we show, the inhibitors greatly slow the fibril formation of the parent proteins of the segments, offering a route to designed chemical interventions and supporting the hypothesis that steric zippers are the principal structural elements of these fibrils.
One of the two fibril-like steric zippers that we have chosen as a target for inhibitor design is the hexapeptide VQIVYK, residues 306-311 of the tau protein, which forms intracellular amyloid fibrils in Alzheimer's disease 17 . This segment has been shown to be important for fibril formation of the full-length protein and itself forms fibrils with biophysical properties similar to full-length tau fibrils 15, 18, 19 . Our second template for inhibitor design, identified by the '3D profile' algorithm 20, 21 , is the steric-zipper structure of the peptide segment GGVLVN from the amyloid fibril formed by 248 PAP 286 , a proteolytic fragment containing residues 248-286 of prostatic acid phosphatase, a protein abundant in semen. 248 
PAP
286 fibrils, also known as semenderived enhancer of virus infection (SEVI), enhance human immunodeficiency virus (HIV) infection by orders of magnitude in cell culture studies, whereas the monomeric peptide is inactive 22 . Our computational approach to designing non-natural peptides that inhibit fibril formation is summarized in Fig. 1 . In both systems, we design a tight interface between the inhibiting peptide and the end of the steric zipper to block additional segments from joining the fibril. By sampling L or D amino acids, or commercially available non-natural amino acids, we can design candidate inhibitors with side chains that maximize hydrogen bonding and hydrophobic interactions across the interface.
We propose that the steric-zipper structures of the VQIVYK and GGVLVN segments represent the spines of the fibrils formed by the parent proteins containing these segments. Supporting our hypothesis are our results that D-amino-acid inhibitors designed on the VQIVYK steric-zipper template inhibit fibril formation not only of the VQIVYK segment, but also of two tau constructs, K12 and K19 23, 24 (Fig. 2a) . Similarly, the peptide composed of non-natural amino acids designed on the GGVLVN template inhibits the fibril formation of 248 PAP 286 and greatly inhibits the HIV infectivity of human cells in culture.
To design a D-amino-acid hexapeptide sequence that interacts favourably with the VQIVYK steric zipper 15 , and prevents further addition of tau molecules to the fibril, we used the Rosetta software 25 . This led to the identification of four D-amino-acid peptides: D-TLKIVW, D-TWKLVL, D-DYYFEF and D-YVIIER, in which the prefix signifies that all a-carbon atoms are in the D configuration (Fig. 2b, (Fig. 2b, c and Supplementary Fig. 1 ), the inhibitor packs tightly across the top of the VQIYVK steric-zipper structure, maintaining all main-chain hydrogen bonds. The side-chain hydrogen bonding between layers of stacked Gln 307 residues is replaced in the designed interface by an interaction with D-Lys 3. Several hydrophobic interactions between D-TLKIVW and the two VQIVYK b-strands contribute to the favourable binding energy (Supplementary Table 1 ). In the design, the D-peptide blocks the addition of another layer of VQIVYK, both above the D-peptide and across on the mating b-sheet ( Supplementary Fig. 3 ). D-Leu 2 of the designed inhibitor prevents the addition of a VQIVYK molecule above it through a steric clash with Ile 308 of VQIVYK and on the mating sheet through a clash with Val 306 and Ile 308 ( Supplementary Fig. 3 ). These steric clashes involving D-Leu 2 are intended to block fibril growth.
We used fluorescence spectroscopy and electron microscopy to assess whether the designed D-peptides inhibit the fibril formation of the tau segment VQIVYK and of the tau constructs K12 and K19. Of our designed inhibitors, D-TLKIVW is the most effective (Supplementary Fig. 4 ). Electron microscopy, performed after three days, verified that incubation with equimolar D-TLKIVW prevents K19 fibril formation, which would otherwise have occurred within the elapsed time (Fig. 1, upper right) . D-TLKIVW delays fibril formation of VQIVYK, K12 and K19 even when present in sub-equimolar concentration ( Supplementary Fig. 5 ). A fivefold molar excess of D-TLKIVW delays K12 fibril formation for more than two weeks in some experimental replicates ( Supplementary Fig. 5c, d ). In tenfold molar excess, D-TLKIVW prevents the fibril formation of K12 for more than 60 hours in the presence of preformed K12 fibril seeds, suggesting that the peptide interacts with fibrils (Fig. 2d) . Also, kinetic analysis shows that the fibril elongation rate decreases in the presence of increasing concentrations of inhibitor peptide ( Supplementary Fig. 6 ). The large increase in lag time in unseeded reactions may be due to interactions with small aggregates formed during the process of fibril formation.
To investigate the specificity of the designed inhibitor, we tested scrambled sequence variants of D-TLKIVW that have poor (that is, high) calculated energies and unfavourable packing (Supplementary Table 1 ). The scrambled peptides D-TIKWVL, D-TIWKVL and D-LKTWIV have little inhibitory effect when present at an equimolar ratio with VQIVYK, K12 and K19 ( Fig. 2e and Supplementary Fig. 7) , showing that the inhibition is sequence specific. Also, the diastereomer, L-TLKIVW, is less effective than D-TLKIVW ( Supplementary Fig. 8 ).
As a further test of the specificity of our design, we confirmed that D-TLKIVW is unable to block the fibril formation of amyloid-b, which also is associated with Alzheimer's disease ( Supplementary Fig. 9 ). This suggests that the D-peptide inhibitor is not general to amyloid systems, but is specific to the VQIVYK interface in tau protein. Such specificity is essential for designed inhibitors if they are not to interfere with proteins that natively function in an amyloid state 3 . To confirm that the designed D-peptide inhibits in accordance with the design model (Fig. 2b, c and Supplementary Fig. 1 ), we performed several additional tests. First we visualized the position of the inhibitor D-TLKIVW relative to fibrils of the tau construct K19 using electron microscopy. We covalently linked Monomaleimido Nanogold particles LETTER RESEARCH both to the inhibitor and, separately, to a scrambled hexapeptide, D-LKTWIV. We used a blind counting assay and found that, relative to Nanogold alone, D-TLKIVW shows a significant binding preference for the end of fibrils, in contrast to the scrambled control peptide, D-LKTWIV ( Fig. 3a and Supplementary Fig. 10) .
As a further test of the model, we used NMR to characterize the binding affinity of D-TLKIVW for tau fibrils. The 1 H NMR spectra for D-TLKIVW were collected in the presence of increasing concentrations of VQIVYK or K19 fibrils. Because neither K19 nor VQIVYK contains tryptophan, we were able to monitor the 1 H resonance of the indole proton of the tryptophan in our inhibitor. When bound to a fibril, the inhibitor, D-TLKIVW, is removed from the soluble phase and the 1 H resonance is diminished 26 ( Fig. 3b and Supplementary Fig.  11 ). As a control, we also measured spectra for the non-inhibiting peptide D-LKTWIV present with D-TLKIVW in the same reaction mixture. As shown in Fig. 3b , the presence of VQIVYK fibrils at a given concentration reduces the D-TLKIVW indole resonance much more than it does the D-LKTWIV indole resonance. Spectra of the two peptides are shown in Supplementary Fig. 12 . By monitoring the D-TLKIVW indole resonance over a range of VQIVYK fibril concentrations, we estimate the apparent dissociation constant of the interaction between D-TLKIVW and VQIVYK fibrils to be ,2 mM (Supplementary Fig. 11a and Methods). This value corresponds to a standard free binding energy of ,7.4 kcal mol 21 , with ,2.5 kcal mol 21 from non-polar interactions and ,4.9 kcal mol 21 from six hydrogen bonds (Methods). Repeating the NMR binding experiment with K19 fibrils yields a similar trend (Supplementary Fig. 11b ). To determine whether D-TLKIVW has affinity for soluble VQIVYK, we measured Fig. 13 ). This, together with the ability of the peptide to prevent seeded fibril formation, suggests that D-TLKIVW does not interact with monomers but rather with a structured, fibril-like species.
As another test of our design model, we replaced the D-Leu residue with D-Ala in D-TLKIVW. Our structural model suggests that D-Leu 2 of D-TLKIVW is important for preventing tau fibril formation because of its favourable interaction with the Ile residue of the VQIVYK molecule below and with Ile and the first Val of VQIVYK across the steric zipper (Fig. 2b, c and Supplementary Fig. 1 ). The D-Ala replacement eliminates these interactions and, furthermore, removes a steric clash that would occur were another VQIVYK molecule placed across from the inhibitor ( Supplementary Fig. 3 and Supplementary Table 1) . When the D-Ala variant is incubated with VQIVYK and the tau constructs, it has no inhibitory effect on fibril formation (Fig. 2f and Supplementary Fig. 14) . This confirms that D-Leu 2 is critical for the efficacy of D-TLKIVW, consistent with our model. In summary, although our electron microscopy, NMR and D-Ala replacement results support a model in which the designed peptide D-TLKIVW binds to the ends of tau fibrils, they do not constitute proof that the inhibitors bind exactly as anticipated in the designs (Supplementary Fig. 15 ).
To expand on our design methodology, we computationally designed an inhibitor of 248 PAP 286 fibril formation containing nonnatural L-amino acids (Fig. 4b and Supplementary Fig. 16 ), using the GGVLVN structure as a template (Fig. 4a and Supplementary Table 2 ). This peptide, Trp-His-Lys-chAla-Trp-hydroxyTic (WW61), contains an Ala derivative, b-cyclohexyl-L-alanine (chAla) and a Tyr/Pro derivative, 7-hydroxy-(S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (hydroxyTic), both of which increase contact area with the GGVLVN template. The non-natural chAla forms hydrophobic interactions with the Leu residue in the steric-zipper interface, and hydroxyTic supports the favourable placement of chAla through hydrophobic packing ( Fig. 4b and Supplementary Fig. 16b ). 
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Moreover, we propose that the bulky side chains and steric constraints of hydroxyTic provide hindrance to further fibril growth.
This designed peptide, WW61, effectively delays both seeded and unseeded fibril formation of 248 
PAP
286 in vitro ( Fig. 4c and Supplementary Figs 17 and 18 ). In the presence of a twofold molar excess of this inhibitor, seeded fibril formation is efficiently blocked for more than two days (Fig. 4c) . Furthermore, we see that increasing the concentration of this inhibitor extends the fibril formation lag time (Supplementary Fig. 19 ). These inhibition assay results were further confirmed by electron microscopy ( Supplementary Fig. 20) . As a control for specificity, we tested the effect of GIHKQK, from the amino terminus of 248 

286
, and PYKLWN, a peptide with the same charge as WW61. Neither peptide affected fibril formation kinetics, indicating that the inhibitory activity of the designed peptide is sequence specific (Supplementary Fig. 21) . Because 248 PAP 286 fibrils (SEVI) have been shown to enhance HIV infection 22 , using a functional assay we investigated whether WW61 is able to prevent this enhancement. In this experiment, we treated HIV particles with 248 PAP 286 solutions that had been agitated for 20 hours (to allow fibril formation) in the presence or absence of WW61, and infected TZM-bl indicator cells. As has been previously observed, SEVI efficiently enhanced HIV infection 22 . However, 248 
PAP
286 incubated with the designed inhibitor prevented HIV infection (Fig. 4d) .
We performed several control experiments to verify that the lack of infectivity observed in the assay is indeed due to the inhibition of SEVI formation. First we confirmed that in the absence of SEVI the designed inhibitor WW61 does not affect HIV infectivity (Supplementary Fig.  22a ). We also found that the control peptides GIHKQK and PYKLWN, which do not inhibit 248 PAP 286 fibril formation, fail to decrease HIV infectivity (Supplementary Fig. 22b ). Additionally, we observed that WW61 has no inhibitory effect on polylysine-mediated HIV infectivity 27 , further ruling out a non-specific electrostatic interaction mechanism (Supplementary Fig. 22a ). Together, these results demonstrate that a peptide capable of preventing 248 
286 fibril formation also inhibits the generation of virus-enhancing material.
Structure-based design of inhibitors of amyloid fibril formation has been challenging in the absence of detailed information about the atomiclevel interactions that form the fibril spine. So far, one of the most successful structure-based approaches to preventing fibril formation has been to stabilize the native tetrameric structure of transthyretin 28 . That approach is well suited to the prevention of fibril formation of proteins with known native structures, but other proteins involved in amyloidrelated diseases, such as tau protein, amyloid-b and 248 PAP 286 , lack fully ordered native structures 29 . Our structure-based approach makes it possible to design inhibitors independent of native structure. Instead, the templates are atomic-level structures of short, fibril-forming segments 14, 15 . By using these fibril-like templates, and adopting computational methods successful in designing novel proteins and proteinprotein interfaces 25, 30 , we have created specific inhibitors of proteins that normally form fibrils. These results support the hypothesis that the steric zipper is a principal feature of tau-related and SEVI fibrils, and suggest that, with current computational methods and steric-zipper structures, we have the tools to design specific inhibitors to prevent the formation of other amyloid fibrils.
METHODS SUMMARY
We used crystal structures of hexapeptide segments of VQIVYK and GGVLVN as templates to design peptide inhibitors using the Rosetta software 25 . Briefly, this algorithm searches possible side-chain conformations (called rotamers) of all amino acids in a peptide b-strand backbone stacked onto the fibril end of both segment structures. The Rosetta software is extended to sample the approximate side-chain conformation of non-natural D and L amino acids by adapting sidechain torsion angles from those in their natural counterparts. The lowest energy set of side-chain rotamers is identified by combinatorial optimization of a potential consisting of a term for the Lennard-Jones potential, an orientationdependent hydrogen-bond potential term, an implicit solvation term and a structure-derived side-chain and backbone torsional potential term. 
METHODS
Computational design. Computational designs were carried out using the Rosetta software 25 (http://www.rosettacommons.org). This algorithm involves building side-chain rotamers of all amino acids onto a fixed protein backbone. The lowest energy set of side-chain rotamers is then identified as those which minimize an energy function containing a Lennard-Jones potential, an orientationdependent hydrogen-bond potential, a solvation term, amino-acid-dependent reference energies and a statistical torsional potential that depends on the backbone and side-chain dihedral angles. D-amino-acid tau inhibitors. The crystal structure of VQIVYK (ref. 15 ; Protein Data Bank ID, 2ON9) was used as a starting scaffold for computational design. To take full advantage of the statistical nature of the rotamer library and some terms in the Rosetta energy function, the stereochemistry of the fibril scaffold was inverted so that design would take place using L amino acids. An extended L-peptide was aligned with the N, C and O backbone atoms of the D-fibril scaffold. This L-peptide was subsequently redesigned, keeping all atoms of the D-fibril fixed. The stereochemistry of the final design model was then inverted, yielding a D-peptide designed to cap an L-fibril. We inspected the finished models to confirm that inversion of the stereochemistry at the Thr and Ile Cb atoms did not make the designs energetically unfavourable. Energetic consequences of incorporating a D inhibitor peptide in the middle of an L fibril were subsequently evaluated to ensure that fibril propagation could not continue after association of an inhibitor. Calculations of the area buried and shape complementarity were performed with AREAIMOL 31 and SC
32
, respectively.
L-peptide 248 PAP 286 inhibitors. The crystal structure of GGVLVN (PDB ID, 3PPD) was used as a template for the following design procedure. An extended L-peptide was aligned according to crystal symmetry. Small, random perturbations of the L-peptide were performed to optimize the rigid-body arrangement between the fibril template and the peptide inhibitor. Full sequence optimization of the inhibitor was performed using the Rosetta software package, allowing residues directly contacting the inhibitor to repack; other scaffold residues remained fixed. Because the design calculations use a discrete rotamer representation of the side chains, we next performed simultaneous quasi-Newtonian optimization of the inhibitor rigid-body orientation, the side-chain torsion angles and, in some cases, the backbone torsion angles using the full-atom Rosetta energy function. This optimization was essential to the subsequent assessment of the inhibition of the design. Several iterative runs of small perturbations in inhibitor placement, interface design and refinement were performed to improve hydrogen-bonding and packing interactions. The designs that ranked highest on the basis of the total binding energy between the inhibitor and the fibril scaffold and the interfacial shape complementarity 32 were subsequently synthesized and tested. For each initial active L-peptide design, the non-natural L amino acids were incorporated using a growth strategy. Non-natural amino acids, structurally similar to those of initial active designs, were selected on the basis of their solubility, side-chain shape and commercial availability. Side-chain conformations were approximately sampled by adopting side-chain torsion angles from those in their natural counterparts. Sequence optimization of the inhibitor was performed and the optimal set of rotamers identified using Monte Carlo simulated annealing with the full-atom energy function described above. The resulting designs were ranked on the basis of the total binding energy between the inhibitor and the fibril scaffold. Tau construct expression and purification. pNG2 expression vectors (derived from pET-3b 33 ) containing either the K12 or K19 gene were provided by E. Mandelkow 34 . Expression in BL21(DE3) Escherichia coli 33 was induced with 1 mM isopropyl thiogalactoside when the absorbance A 600 nm was between 0.8 and 1.0, and cells were collected after 3-4 h. K12 and K19 were purified on the basis of previously described methods 35 . Cells were pelleted for 20 min at 4,700g and resuspended in 20 mM MES, pH 6.8, 1 mM EDTA, 0.2 mM MgCl 2 , 5 mM DTT, 1 mM PMSF and a protease inhibitor cocktail. The cells were sonicated for 2.5 min and, following addition of NaCl to bring cell lysate to 0.5 M NaCl, the lysate was boiled for 20 min. The lysate was sedimented at 30,000g for 20 min and dialyzed twice against 20 mM MES, pH 6.8, 50 mM NaCl, 1 mM EDTA, 1 mM MgCl 2 , 2 mM DTT and 0.1 mM PMSF at 4 uC. The dialysate was pelleted for 20 min at 30,000g and filtered before cation exchange chromatography on an AKTA Explorer (GE Pharmacia) with a HighTrap HP SP 5-ml column (GE Healthcare). The sample was eluted with a linear gradient of up to 60% buffer B (20 mM MES, pH 6.8, 1 M NaCl, 1 mM EDTA, 1 mM MgCl 2 , 2 mM DTT and 0.1 mM PMSF). Size exclusion chromatography was optionally performed with a Superdex 75 10/300 GL column (GE Healthcare) in PBS buffer (137 mM NaCl, 3 mM KCl, 10 mM Na 2 HPO 4 , 2 mM KH 2 PO 4 , pH 7.4) with 1 mM DTT on the AKTA Explorer depending on preparation purity as assessed by SDS polyacrylamide gel electrophoresis. Tau construct inhibition assays. Fibril formation assays were performed on the basis of previously published protocols [35] [36] [37] [38] . Reaction mixtures (150 ml) containing 50 mM tau K12 or K19, as determined by the Micro BCA Protein Assay Kit (Pierce), were incubated in 250 mM sodium phosphate buffer, pH 7.4, with 1 mM DTT, 12.5 mM heparin (average molecular mass, 6,000 Da; Sigma) and 10 mM Thioflavin S (ThS; MP Bio). Inhibitor peptides (CS Bio, Celtek Biosciences) were dissolved in 250 mM phosphate buffer, pH 7.4, to 0.5 mM and added at specified molar ratios. Reactions were split into a minimum of three replicates in black, 96-well, optically clear plates (Nunc), sealed with Corning pressure-sensitive sealing tape and monitored using either a Varioskan plate reader (Thermo Scientific), for K12, or a SpectraMax M5, for K19. The fluorescence signal was measured every 15 min with excitation and emission wavelengths of 440 and 510 nm, respectively, at 37 uC, with continuous shaking at 900 r.p.m. with a diameter of 1 mm for K12, and with quiescent incubation with shaking 2 s before each reading for K19. Plots showing the fluorescence trace of the replicate with median lag time for each sample were created using R 39 . Plots of lag time depict the mean time value at which each replicate crossed an arbitrary fluorescence value above noise background (values were selected per experiment and applied to all samples). Error bars represent the standard deviation of the replicate lag times for each sample. Seeded K12 fibril formation assays. Seeds were produced by incubating 50 mM K12 as above, but without ThS present, and were added at 0.25% (v/v). Peptide stock concentrations were 0.75 mM and were added at a final concentration of tenfold molar excess relative to soluble K12. Reaction mixtures were otherwise prepared and monitored as above. VQIVYK inhibition assays. The VQIVYK fibril formation assay was modified from a previously published protocol 40 . Buffers and plates were kept on ice to delay VQIVYK fibril formation while the reaction mixtures were prepared. Replicate solutions of 180 ml of 25 mM MOPS, pH 7.2, 100 mM ThS and inhibitor peptides were added to black, clear-bottomed, 96-well Nunc plates with 1/8-inch PTFE beads (Orange Products). Acetylated and amidated VQIVYK (Genscript) was dissolved in H 2 O to 1.3 mM and filtered through a Millipore Microcon 100-kDa filter device at 14,000g for 5 min at 4 uC to remove large aggregates (final concentration, ,1 mM). Filtered VQIVYK (20 ml) was added to each reaction well. ThS fluorescence was monitored at room temperature every 2 min using a SpectraMax M5 fluorometer with 2 s of mixing before each reading. Amyloid-b fibril formation assay. Lyophilized amyloid-b(1-42) was diluted to 0.2 mg ml 21 in 50 mM NH 4 OH and filtered with a 0.2-mm filter. The reaction mixture contained a final concentration of 11.5 mM amyloid-b(1-42), 10 mM Thioflavin T (ThT), 23 mM NH 4 OH in 100 mM bicine, pH 9.1, and 11.5 mM D-TLKIVW in reactions with peptide present. Reactions were split into four replicates and the ThT fluorescence signal was measured every minute (excitation wavelength, 440 nm; emission wavelength, 510 nm), at 37 uC, with continuous shaking at 960 r.p.m. with a 1-mm diameter in a Varioskan fluorometer. Electron microscopy. Sample (5 ml) was applied to glow-discharged, 400-mesh carbon-coated, formvar films on copper grids (Ted Pella) for 3 min. Grids were rinsed twice with distilled water and stained with 1% uranyl acetate for 90 s. Grids were examined in a Hitachi H-7000 transmission electron microscope at 75 keV or a JEOL JEM1200-EX operating at 80 keV. Tau fibril formation kinetic analysis. The nucleation (k 1 ) and propagation (k 2 ) rates were determined by fitting the form of the Finke-Watzky two-step mechanism 41 . Plateau values were determined and the remaining parameters were fitted using the 'leasqr' nonlinear least-squares regression function (http://fly.isti.cnr.it/ pub/software/octave/leasqr/) through the OCTAVE software package (http:// www.gnu.org/software/octave/). Preparation of peptide-gold conjugates. Peptide-Nanogold conjugates were prepared as described earlier for similarly sized peptides 42 . Briefly, 60 nmol of the peptides CGGG-(D)-TLKIVW and CGGG-(D)-LKTWIV (CS Bio) were dissolved in 110 ml of phosphate-buffered saline (20 mM, pH 6.5, 0.15 M NaCl), added to 6 nmol of Monomaleimido Nanogold (Nanoprobes), dissolved in 200 ml H 2 O and incubated for 1 h at room temperature (22 uC) with constant rotation. Peptide-Nanogold conjugates were separated from excess unbound peptides by membrane centrifugation (Microcon-10 system, Amicon) using a molecular mass cut-off of 10 kDa. Peptide-Nanogold conjugates were then diluted into phosphatebuffered saline, aliquoted and stored at 220 uC for no longer than one month. Preparation of K19 fibrils. K19 fibrils were generated by incubating 100 mM soluble K19 with 25 mM 6-kDa heparin overnight at 37 uC in phosphate buffer (50 mM, pH 7.4). K19 fibrils were sonicated for 15 s, using a microtip set to 35% amplitude. Residual heparin and small oligomers were removed by centrifuging the mixture through a 100-kDa Microcon concentrator for 10 min at 14,000g, washing the retentate with phosphate buffer and repeating three times; the retentate was restored to its original volume with phosphate buffer. These short fibril segments were stored at 4 uC for no longer than one week. For NMR studies, fibril samples were similarly prepared, but were washed in H 2 O and concentrated to 2 mM K19 (by monomer).
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